HCV combination therapy

Details HCV combination therapy HCV combination therapy

2005-02-01

2005-02-01

Andres, Janet L. (Department: 1646)

Drug, bio-affecting and body treating compositions

Lymphokine

Interferon

C424S085400, C514S042000, C514S458000, C514S474000

Reexamination Certificate

active

06849254

ABSTRACT:
Methods of treating patients having susceptible viral infections, especially chronic hepatitis C infection by administering to said patient a therapeutically effective amount of a combination therapy of interferon-alfa and ribavirin for a time sufficient to lower HCV-RNA in association with a therapeutically effective amount of an antioxidant for a time sufficient to ameliorate ribavirin-related hemolysis are disclosed.

REFERENCES:
patent: 4917888 (1990-04-01), Katre et al.
patent: 5951974 (1999-09-01), Gilbert et al.
patent: 6172046 (2001-01-01), Albrecht
patent: 6472373 (2002-10-01), Albrecht
patent: WO 9819670 (1998-05-01), None
Sies et al. Am. J. Clin Nutr., 1995, vol. 62, pp. 1315S-1321S.*
www.bayercare.com, One-A-Day 50 Plus and One-A-Day Antioxidant product sheets.*
Abella et al. Brit. J. Clin. Pharmacol., 1996, vol. 42, pp. 731-747.*
Brass, C.A., et al., “Do Antioxidants Ameliorate Ribavirin Related Anemia in HCV Patients”, Gastroenterology, (Apr., 1999) vol. 116, No. 4, Part 2, pp. A1192-A1193 (Mail date Mar. 24, 1999).
G.L. Davis, et al., N. Eng. J. Med., 1998, 339:1493-1499.
John G. McHutchinson, et al, N. Eng. J. Med., 1998, 339: 1485-1492.
T. Poynard, et al. , The Lancet, 1998, vol. 352, Oct. 31, pp. 1426-1432.
Reichard, et al., The Lancet, 1998; 351'83-87.
Shulman, Clinical Assessment of Hematologic Effects of Ribavirin in Humans, 1984, pp 79-92.

Affiliated with

Also associated with

Rating

HCV combination therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with HCV combination therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HCV combination therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3470604